아이슬란드 - 아이슬란드어 - LYFJASTOFNUN (Icelandic Medicines Agency)

stada arzneimittel ag - ondansetronum hýdróklóríð - filmuhúðuð tafla - 8 mg

아이슬란드 - 아이슬란드어 - LYFJASTOFNUN (Icelandic Medicines Agency)

stada arzneimittel ag - ondansetronum hýdróklóríð - filmuhúðuð tafla - 4 mg

유럽 연합 - 아이슬란드어 - EMA (European Medicines Agency)

pfizer europe ma eeig - parecoxibnatríum - verkir, eftir aðgerð - coxibs, antiinflammatory and antirheumatic products - til skammvinnrar meðhöndlunar á verkjum eftir aðgerð hjá fullorðnum.

유럽 연합 - 아이슬란드어 - EMA (European Medicines Agency)

astrazeneca ab - saxagliptin - sykursýki, tegund 2 - lyf notuð við sykursýki - add-on combination therapyonglyza is indicated in adult patients aged 18 years and older with type-2 diabetes mellitus to improve glycaemic control:as monotherapy:in patients inadequately controlled by diet and exercise alone and for whom metformin is inappropriate due to contraindications or intolerance;as dual oral therapy:in combination with metformin, when metformin alone, with diet and exercise, does not provide adequate glycaemic control;in combination with a sulphonylurea, when the sulphonylurea alone, with diet and exercise, does not provide adequate glycaemic control in patients for whom use of metformin is considered inappropriate;in combination with a thiazolidinedione, when the thiazolidinedione alone with diet and exercise, does not provide adequate glycaemic control in patients for whom use of a thiazolidinedione is considered appropriate;as triple oral therapy:in combination with metformin plus a sulphonylurea when this regimen alone, with diet and exercise, does not provide adequate glycaemic control;as combination therapy with insulin (with or without metformin), when this regimen alone, with diet and exercise, does not provide adequate glycaemic control.

유럽 연합 - 아이슬란드어 - EMA (European Medicines Agency)

blueprint medicines (netherlands) b.v. - avapritinib - gastrointestinal stromal tumors - Önnur antineoplastic lyf, prótín nt-hemlar - ayvakyt is indicated as monotherapy for the treatment of adult patients with unresectable or metastatic gastrointestinal stromal tumours (gist) harbouring the platelet-derived growth factor receptor alpha (pdgfra) d842v mutation.

유럽 연합 - 아이슬란드어 - EMA (European Medicines Agency)

astellas pharma europe b.v. - enzalutamíð - blöðruhálskirtli - innkirtla meðferð - xtandi is indicated for:the treatment of adult men with metastatic hormone-sensitive prostate cancer (mhspc) in combination with androgen deprivation therapy (see section 5. the treatment of adult men with high-risk non-metastatic castration-resistant prostate cancer (crpc) (see section 5. the treatment of adult men with metastatic crpc who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated (see section 5. the treatment of adult men with metastatic crpc whose disease has progressed on or after docetaxel therapy.

유럽 연합 - 아이슬란드어 - EMA (European Medicines Agency)

teva b.v. - zoledronsýra - osteoporosis; osteitis deformans; osteoporosis, postmenopausal - lyf til að meðhöndla beinsjúkdóma - treatment of osteoporosis: , in post-menopausal women;, in men; , at increased risk of fracture including those with a recent low-trauma hip fracture. treatment of osteoporosis associated with long-term systemic glucocorticoid therapy: , in post-menopausal women;, in men; , at increased risk of fracture. meðferð gerðar voru á fyrirbyggjandi er sjúkdómur bein í fullorðnir.

유럽 연합 - 아이슬란드어 - EMA (European Medicines Agency)

sanofi winthrop industrie - cabazitaxel - blöðruhálskirtli - Æxlishemjandi lyf - jevtana ásamt prednisone eða prednisólóni er ætlað fyrir sjúklinga með hormón-svarar sjúklingum krabbamein í blöðruhálskirtli áður meðhöndluð með docetaxel-inniheldur meðferð.

유럽 연합 - 아이슬란드어 - EMA (European Medicines Agency)

accord healthcare s.l.u. - cabazitaxel - stækkun Æxli, gelding-Þola - Æxlishemjandi lyf - treatment of patients with hormone refractory metastatic prostate cancer previously treated with a docetaxel-containing regimen.